UK Probiotics Market - Forecasts from 2020 to 2025
UK Probiotics Market is expected to grow at a compound annual growth rate of 5.87% over the forecast period to reach a market size of US$1,566.094 million in 2025 from US$1,112.005 million in 2019. Probiotics are effective in improving gut-related disorders related to digestion, intestinal tracts, and bowel function. Growing awareness among the consumers of the UK regarding the relationship between diet and health is strengthening the demand for probiotic food and beverage products and dietary supplements that enhance health while providing basic nutrition. The market for the ingredients used in probiotics for poultry has been rising steadily over the years due to the enormous demand for meat consumption worldwide as well as ab aversion towards red meat consumption. Poultry probiotic ingredients are usually utilized as feed additives to improve feed efficiency and development execution in ruminants, pigs, aquaculture, and poultry animals. There is also considerable research that has shown that the benefits of consuming probiotic drinks could become a valid remedial measure that will address antibiotic-resistant bacteria. This new development comes after a team of scientists at the University of Birmingham engineered and patented a key genetic element that can tackle the genetic basis of resistance. Further, as per a research carried by Imperial College London and the University of Nottingham in the UK, taking a daily probiotic supplement from 36-38 weeks pregnancy, and during the first three to six months of breastfeeding, reduced the risk of a child developing eczema by a certain percentage.
Besides, there has been considerable development in recent times as far as market players of probiotics for human consumption (internal or topical) is concerned. These developments are a testimony to the growing demand for probiotics for human consumption. Thereby, signaling a healthy UK Probiotics Market growth during the forecast period. To this end, it may be noted In February 2020, SkinBioTherapeutics plc, a life science company focused on skin health, announces that its wholly-owned subsidiary, AxisBiotix Limited, has signed a development agreement with Winclove Probiotics B.V., a specialist in the research, development, and manufacture of probiotic food formulations and supplements, to help manage the symptoms associated with the skin condition, psoriasis. SkinBioTherapeutics and Winclove will design and develop a probiotic blend of 'good' bacterial strains based on the modifying properties of specific bacterial species on known psoriasis disease pathways.
As of January 2020, the nutraceutical and Cannabinoid manufacturers Medlab was reportedly teaming up with UK-based distributors Cultech to expand its probiotic products among others into Europe. It is a three-year deal that will facilitate the expansion of the Australian firm’s nutraceutical section of its business whereby the customers of UK will be able to purchase its patented probiotic rehydration formulation ORSBiotic, which is a patented formulation that reduces the occurrence of diarrhea in children’s which often leads to dehydration. It is also reported to supplement electrolytes and support gastrointestinal system health. The formulation has been reported to contain the probiotic species Saccharomyces Boulardii and zinc which is expected to aid in the reduction of the occurrence of diarrhea.
Earlier in 2017, SkinBioTherapeutics, a spin-out from the University of Manchester, debuted in AIM, the London Stock Exchange’s market for smaller growing companies. It had reportedly raised funding to continue the development and accelerate clinical development of the company’s SkinBiotix technology, which encompasses products that are based on extracts of probiotic organisms. The rationale behind this development was to develop a product with probiotics that would have therapeutic action on the skin.
Segmentation
§ Bifidobacterium
§ Streptococcus Thermophilus
Besides, there has been considerable development in recent times as far as market players of probiotics for human consumption (internal or topical) is concerned. These developments are a testimony to the growing demand for probiotics for human consumption. Thereby, signaling a healthy UK Probiotics Market growth during the forecast period. To this end, it may be noted In February 2020, SkinBioTherapeutics plc, a life science company focused on skin health, announces that its wholly-owned subsidiary, AxisBiotix Limited, has signed a development agreement with Winclove Probiotics B.V., a specialist in the research, development, and manufacture of probiotic food formulations and supplements, to help manage the symptoms associated with the skin condition, psoriasis. SkinBioTherapeutics and Winclove will design and develop a probiotic blend of 'good' bacterial strains based on the modifying properties of specific bacterial species on known psoriasis disease pathways.
As of January 2020, the nutraceutical and Cannabinoid manufacturers Medlab was reportedly teaming up with UK-based distributors Cultech to expand its probiotic products among others into Europe. It is a three-year deal that will facilitate the expansion of the Australian firm’s nutraceutical section of its business whereby the customers of UK will be able to purchase its patented probiotic rehydration formulation ORSBiotic, which is a patented formulation that reduces the occurrence of diarrhea in children’s which often leads to dehydration. It is also reported to supplement electrolytes and support gastrointestinal system health. The formulation has been reported to contain the probiotic species Saccharomyces Boulardii and zinc which is expected to aid in the reduction of the occurrence of diarrhea.
Earlier in 2017, SkinBioTherapeutics, a spin-out from the University of Manchester, debuted in AIM, the London Stock Exchange’s market for smaller growing companies. It had reportedly raised funding to continue the development and accelerate clinical development of the company’s SkinBiotix technology, which encompasses products that are based on extracts of probiotic organisms. The rationale behind this development was to develop a product with probiotics that would have therapeutic action on the skin.
Segmentation
- By Application
- Functional Food and Beverages
- Dietary Supplements
- Animal Feed
- By Ingredient
- Bacteria
§ Bifidobacterium
§ Streptococcus Thermophilus
- Yeast
- By Form
- Liquid
- Dry
- By Application
- Functional Food and Beverages
- Dietary Supplements
- Animal Feed
- By End-User
- Human
- Animal
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. UK PROBIOTICS MARKET, BY APPLICATION
5.1. Introduction
5.2. Functional Food and Beverages
5.3. Dietary Supplements
5.4. Animal Feed
6. UK PROBIOTICS MARKET, BY END-USER
6.1. Introduction
6.2. Human
6.3. Animal
7. UK PROBIOTICS MARKET, BY INGREDIENTS
7.1. Introduction
7.2. Bacteria
7.2.1. Lactobacilli
7.2.2. Bifidobacterium
7.2.3. Streptococcus Thermophilus
7.2.4. Others
7.3. Yeast
8. UK PROBIOTICS MARKET, BY FUNCTION
8.1. Introduction
8.2. Regular
8.3. Preventative Healthcare
8.4. Therapeutic
9. UK PROBIOTICS MARKET, BY TYPE
9.1. Introduction
9.2. Lactobacillus
9.3. Streptococcus
9.4. Bifidobacterium
9.5. Spore Formers
9.6. Others
10. UK PROBIOTICS MARKET, BY FORM
10.1. Introduction
10.2. Liquid
10.3. Dry
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Emerging Players and Market Lucrativeness
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Vendor Competitiveness Matrix
12. COMPANY PROFILES
12.1. Aliment Ltd
12.2. BELLAVIE srl
12.3. Lallemand
12.4. Natren UK
12.5. Nestl?
12.6. Pfizer Inc.
12.7. Protexin
12.8. ProVen Probiotics
12.9. Wren Laboratories
12.10. Yakult
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. UK PROBIOTICS MARKET, BY APPLICATION
5.1. Introduction
5.2. Functional Food and Beverages
5.3. Dietary Supplements
5.4. Animal Feed
6. UK PROBIOTICS MARKET, BY END-USER
6.1. Introduction
6.2. Human
6.3. Animal
7. UK PROBIOTICS MARKET, BY INGREDIENTS
7.1. Introduction
7.2. Bacteria
7.2.1. Lactobacilli
7.2.2. Bifidobacterium
7.2.3. Streptococcus Thermophilus
7.2.4. Others
7.3. Yeast
8. UK PROBIOTICS MARKET, BY FUNCTION
8.1. Introduction
8.2. Regular
8.3. Preventative Healthcare
8.4. Therapeutic
9. UK PROBIOTICS MARKET, BY TYPE
9.1. Introduction
9.2. Lactobacillus
9.3. Streptococcus
9.4. Bifidobacterium
9.5. Spore Formers
9.6. Others
10. UK PROBIOTICS MARKET, BY FORM
10.1. Introduction
10.2. Liquid
10.3. Dry
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Emerging Players and Market Lucrativeness
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Vendor Competitiveness Matrix
12. COMPANY PROFILES
12.1. Aliment Ltd
12.2. BELLAVIE srl
12.3. Lallemand
12.4. Natren UK
12.5. Nestl?
12.6. Pfizer Inc.
12.7. Protexin
12.8. ProVen Probiotics
12.9. Wren Laboratories
12.10. Yakult
